|Brand name(s), other common name(s)||BosulifTM|
|Drug type||Tyrosine kinase inhibitor (TKI)|
|How the drug is given||By mouth|
Bosutinib is FDA approved for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy.
Side effects needing medical attention:Diarrhea; nausea; vomiting; abdominal pain; low blood cell counts; rash; anemia; fever; fatigue; headache; dizziness; cough; anaphylactic shock; myelosuppression; fluid retention; liver damage; rash.